title: Bevacizumab: one treatment for all the seasons?
authors.forename: Alain J
authors.initials: AJ
authors.lastname: Gelibter
authors.forename: Susanna
authors.initials: S
authors.lastname: Di Segni
authors.forename: Massimo
authors.initials: M
authors.lastname: Zeuli
authors.forename: Francesco
authors.initials: F
authors.lastname: Cognetti
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab